The use of PEGylated liposomes in the development of drug delivery applications for the treatment of hemophilia

International Journal of Nanomedicine

Volumn 5, Issue 1, 2010, Pages 581-591

  Yatuv, Rivka ^a   Robinson, Micah ^a   Dayan Tarshish, Inbal ^a   Baru, Moshe ^a  

^a Omri Laboratories Ltd   (Israel)

Author keywords

Factor VIIa; Factor VIII; Pegylated liposomes; Pharmacodynamics; Therapeutic proteins

Indexed keywords

BAY 79 4980; BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 8; LIPOSOME; MACROGOL; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT BLOOD CLOTTING FACTOR 8; UNCLASSIFIED DRUG; MACROGOL DERIVATIVE;

AMINO ACID SEQUENCE; ANXIETY; BLEEDING DISORDER; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; ENCAPSULATION; FLUSHING; HEMOPHILIA; HEMOPHILIA A; HUMAN; HYPEREMIA; HYPERTENSION; HYPERVENTILATION; LIPOSOMAL DELIVERY; NONHUMAN; PATIENT ATTITUDE; PATIENT COMPLIANCE; PHARMACODYNAMICS; PROTEIN BINDING; PROTEIN MODIFICATION; QUALITY OF LIFE; REVIEW; SIDE EFFECT; SURFACE PROPERTY; ANIMAL; BLOOD; CHEMISTRY; CONSENSUS SEQUENCE; DELAYED RELEASE FORMULATION; DISEASE MODEL; DRUG DELIVERY SYSTEM; GENETICS; METHODOLOGY; MOUSE; NANOMEDICINE;

AMINO ACID SEQUENCE; ANIMALS; CHEMISTRY, PHARMACEUTICAL; CONSENSUS SEQUENCE; DELAYED-ACTION PREPARATIONS; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; FACTOR VIIA; FACTOR VIII; HEMOPHILIA A; HUMANS; LIPOSOMES; MICE; NANOMEDICINE; POLYETHYLENE GLYCOLS;

EID: 79952115967     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: None     Document Type: Review

References (62)

1. Dahlback B. Blood coagulation and its regulation by anticoagulant pathways: genetic pathogenesis of bleeding and thrombotic diseases. J Intern Med. 2005;257:209-223.
2. Hedner U, Ginsburg D, Lusher JM, High KA. Congenital Hemorrhagic Disorders: New Insights into the Pathophysiology and Treatment of Hemophilia. Hematology Am Soc Hematol Educ Program. 2000: 241-265.
3. Soucie JM, Evatt B, Jackson D. Occurrence of hemophilia in the United States. The Hemophilia Surveillance System Project Investigators. Am J Hematol. 1998;59:288-294.
4. Kaufman RJ, Anthonorakis SE, Fay PJ. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 4th ed. Philadelphia: Lippincott Williams and Wilkins, 2001.
5. Roosendaal G, Mauser-Bunschoten EP, De Kleijn P, et al. Synovium in haemophilic arthropathy. Haemophilia. 1998;4:502-505.
6. Arun B, Kessler C. Inherited hemorrhagic disorders. In: Colman W, Hirsh J, Marder V, Clowes A, George J, editors. Hemostasis and thrombosis. 4th ed. Philadelphia: Lippincott Williams & Willkins, 2001:815-825.
7. Hoots WK, Nugent DJ. Evidence for the benefits of prophylaxis in the management of hemophilia A. Thromb Haemost. 2006;96:433-440.
8. Kessler CM. New perspectives in hemophilia treatment. Hematology Am Soc Hematol Educ Program. 2005:429-435.
9. Jankowski MA, Patel H, Rouse JC, Marzilli LA, Weston SB, Sharpe PJ. Defining 'full-length' recombinant factor VIII: a comparative structural analysis. Haemophilia. 2007;13:30-37.
10. Fijnvandraat K, Berntorp E, ten Cate JW, et al. Recombinant, B-domain deleted factor VIII (r-VIII SQ): pharmacokinetics and initial safety aspects in hemophilia A patients. Thromb Haemost. 1997;77:298-302.
11. Weiss HJ, Sussman, II, Hoyer LW. Stabilization of factor VIII in plasma by the von Willebrand factor. Studies on posttransfusion and dissociated factor VIII and in patients with von Willebrand's disease. J Clin Invest. 1977;60:390-404.
12. Santagostino E, Mancuso ME. Barriers to primary prophylaxis in haemophilic children: the issue of the venous access. Blood Transfus. 2008;6:S12-S16.
13. Saenko EL, Ananyeva NM, Moayeri M, Ramezani A, Hawley RG. Development of improved factor VIII molecules and new gene transfer approaches for hemophilia A. Curr Gene Ther. 2003;3:27-41.
14. Mathew P. Current opinion on inhibitor treatment options. Semin Hematol. 2006;43:S8-S13.
15. Lusher JM, Roberts HR, Davignon G, et al. A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. rFVIIa Study Group. Haemophilia. 1998;4:790-798.
16. Shapiro A. Inhibitor treatment: state of the art. Dis Mon. 2003;49: 22-38.
17. Rick ME, Walsh CE, Key NS. Congenital bleeding disorders. Hematology Am Soc Hematol Educ Program. 2003:559-574.
18. Zeitler H, Ulrich-Merzenich G, Hess L, et al. Treatment of acquired hemophilia by the Bonn-Malmo Protocol: documentation of an in vivo immunomodulating concept. Blood. 2005;105:2287-2293.
19. Ma AD, Carrizosa D. Acquired factor VIII inhibitors: pathophysiology and treatment. Hematology Am Soc Hematol Educ Program. 2006: 432-437.
20. Kempton CL, White GC 2nd. How we treat a hemophilia A patient with a factor VIII inhibitor. Blood. 2009;113:11-17.
21. Tjonnfjord GE, Holme PA. Factor eight inhibitor bypass activity (FEIBA) in the management of bleeds in hemophilia patients with high-titer inhibitors. Vasc Health Risk Manag. 2007;3:527-531.
22. Hedner U, Glazer S, Pingel K, et al. Successful use of recombinant factor VIIa in patient with severe haemophilia A during synovectomy. Lancet. 1988;2:1193.
23. Ingerslev J. Efficacy and safety of recombinant factor VIIa in the prophylaxis of bleeding in various surgical procedures in hemophilic patients with factor VIII and factor IX inhibitors. Semin Thromb Hemost. 2000;26:425-432.
24. Fridberg MJ, Hedner U, Roberts HR, Erhardtsen E. A study of the pharmacokinetics and safety of recombinant activated factor VII in healthy Caucasian and Japanese subjects. Blood Coagul Fibrinolysis. 2005;16:259-266.
25. Lindley CM, Sawyer WT, Macik BG, et al. Pharmacokinetics and pharmacodynamics of recombinant factor VIIa. Clin Pharmacol Ther. 1994;55:638-648.
26. Ingerslev J, Thykjaer H, Kudsk Jensen O, Fredberg U. Home treatment with recombinant activated factor VII: results from one centre. Blood Coagul Fibrinolysis. 1998;9:S107-S110.
27. Key NS, Aledort LM, Beardsley D, et al. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors. J Thromb Haemost. 1998;80: 912-918.
28. Gale EL, Pipe SW. Strategies towards a longer acting factor VIII. Haemophilia. 2006;12 Suppl 3:42-51.
29. Gale AJ, Pellequer JL. An engineered interdomain disulfide bond stabilizes human blood coagulation factor VIIIa. J Thromb Haemost. 2003;1:1966-1971.
30. Gale AJ, Radtke KP, Cunningham MA, Chamberlain D, Pellequer JL, Griffin JH. Intrinsic stability and functional properties of disulfide bond-stabilized coagulation factor VIIIa variants. J Thromb Haemost. 2006;4:1315-2132.
31. Pipe SW, Kaufman RJ. Characterization of a genetically engineered inactivation-resistant coagulation factor VIIIa. Proc Natl Acad Sci U S A. 1997;94:11851-11856.
32. Mei B, Pan C, Jiang H, et al. Rational design of a fully active, longacting PEGylated factor VIII for hemophilia A treatment. Blood.
33. Murphy JE, Pan C, Barnett T, et al. Site-specific PEGylation of rFVIII results in prolonged in vivo efficacy. J Thromb Haemost. 2007;5: P-T-022.
34. Regan LM, Jiang X, Ramsey P, et al. Biological activity of PEGylated factor VIII. J Thromb Haemost. 2007;5:P-T-026.
35. Tang L, Pan C, Atwal H, et al. PEGylation protects factor VIII from the inhibition of antibody inhibitors. J Thromb Haemost. 2007;5: P-T-036.
36. Allen GA, Persson E, Campbell RA, Ezban M, Hedner U, Wolberg AS. A variant of recombinant factor VIIa with enhanced procoagulant and antifibrinolytic activities in an in vitro model of hemophilia. Arterioscler Thromb Vasc Biol. 2007;27:683-689.
37. Stennicke HR, Ostergaard H, Bayer RJ, et al. Generation and biochemical characterization of glycoPEGylated factor VIIa derivatives. J Thromb Haemost. 2008;100:920-928.
38. Schulte S. Use of albumin fusion technology to prolong the half-life of recombinant factor VIIa. Thromb Res. 2008;122:S14-S19.
39. Zamboni WC. Concept and clinical evaluation of carrier-mediated anticancer agents. Oncologist. 2008;13:248-260.
40. Elbayoumi TA, Torchilin VP. Liposomes for targeted delivery of antithrombotic drugs. Expert Opin Drug Deliv. 2008;5:1185-1198.
41. Gabizon A, Shmeeda H, Barenholz Y. Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies. Clin Pharmacokinet. 2003;42:419-436.
42. Gabizon A, Catane R, Uziely B, et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res. 1994; 54:987-992.
43. Gabizon AA, Barenholz Y, Bialer M. Prolongation of the circulation time of doxorubicin encapsulated in liposomes containing a polyethylene glycol-derivatized phospholipid: pharmacokinetic studies in rodents and dogs. Pharm Res. 1993;10:703-708.
44. Klibanov AL, Maruyama K, Torchilin VP, Huang L. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett. 1990;268:235-237.
45. Baru M, Carmel-Goren L, Barenholz Y, et al. Factor VIII efficient and specific non-covalent binding to PEGylated liposomes enables prolongation of its circulation time and haemostatic efficacy. J Thromb Haemost. 2005;93:1061-1068.
46. Dayan I, Robinson M, Baru M. Enhancement of haemostatic efficacy of plasma-derived FVIII by formulation with PEGylated liposomes. Haemophilia. 2009;15:1006-1013.
47. Yatuv R, Dayan I, Carmel-Goren L, et al. Enhancement of factor VIIa haemostatic efficacy by formulation with PEGylated liposomes. Haemophilia. 2008;14:476-483.
48. Yatuv R, Carmel-Goren L, Dayan I, Robinson M, Baru M. Binding of proteins to PEGylated liposomes and improvement of G-CSF efficacy in mobilization of hematopoietic stem cells. J Control Release. 2009;135:44-50.
49. Spira J, Plyushch OP, Andreeva TA, Andreev Y. Prolonged bleedingfree period following prophylactic infusion of recombinant factor VIII reconstituted with pegylated liposomes. Blood. 2006;108:3668-3673.
50. Pan J, Liu T, Kim JY, et al. Enhanced efficacy of recombinant FVIII in noncovalent complex with PEGylated liposome in hemophilia A mice. Blood. 2009;114:2802-2811.
51. Powell JS. Liposomal approach towards the development of a longeracting factor VIII. Haemophilia. 2007;13:23-28.
52. Spira J, Plyushch OP, Andreeva TA, Khametova RN. Evaluation of liposomal dose in recombinant factor VIII reconstituted with pegylated liposomes for the treatment of patients with severe haemophilia A. J Thromb Haemost. 2008;100:429-434.
53. Powell JS, Nugent DJ, Harrison JA, et al. Safety and pharmacokinetics of a recombinant factor VIII with pegylated liposomes in severe hemophilia A. J Thromb Haemost. 2008;6:277-283.
54. Martinowitz U, Lalezari S, Luboshitz J, Lubetsky A, Spira J. Infusion rates of recombinant FVIII-FS with PEGylated liposomes in haemophilia A. Haemophilia. 2008;14:1122-1124.
55. Szebeni J. Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity. Toxicology. 2005;216:106-121.
56. Spira J, Plyushch OP, Zozulya N, et al. Safety, pharmacokinetics and efficacy of factor VIIa formulated with PEGylated liposomes in haemophilia A patients with inhibitors to factor VIII. An open label, exploratory, cross over, phase I/II study. Haemophilia. 2010; In Press.
57. Yatuv R, Robinson M, Dayan I, Baru M. Enhancement of the efficacy of therapeutic proteins by formulation with PEGylated liposomes; a case of FVIII, FVIIa and G-CSF. Expert Opin Drug Deliv. 2010;7:187-201.
58. Constantinescu I, Levin E, Gyongyossy-Issa M. Liposomes and blood cells: a flow cytometric study. Artif Cells Blood Substit Immobil Biotechnol. 2003;31:395-424.
59. High KA. The leak stops here: platelets as delivery vehicles for coagulation factors. J Clin Invest. 2006;116:1840-1842.
60. Laub R, Di Giambattista M, Fondu P, et al. Inhibitors in German hemophilia A patients treated with a double virus inactivated factor VIII concentrate bind to the C2 domain of FVIII light chain. J Thromb Haemost. 1999;81:39-44.
61. Raut S, Di Giambattista M, Bevan SA, Hubbard AR, Barrowcliffe TW, Laub R. Modification of factor VIII in therapeutic concentrates after virus inactivation by solvent-detergent and pasteurisation. J Thromb Haemost. 1998;80:624-631.
62. Kanter PM, Bullard GA, Pilkiewicz FG, Mayer LD, Cullis PR, Pavelic ZP. Preclinical toxicology study of liposome encapsulated doxorubicin (TLC D-99): comparison with doxorubicin and empty liposomes in mice and dogs. In Vivo. 1993;7:85-95.